Madrigal outlines 2027 F4c outcomes readout while reinforcing mid- to high 30s 2026 gross-to-net outlook (NASDAQ:MDGL)
· seekingalpha.com
Madrigal (MDGL) Q2 2026 earnings call: Rezdiffra sales hit $364M, 50K patients, gross-to-net outlook, and 2027 trial catalysts.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...